Human alpha-galactosidase variants
US11427813B2 · kind B2 · utility
3Cited by
107References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 19, 2019 |
| Grant date | Aug 30, 2022 |
| Priority date | — |
| Expiry date | Feb 21, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y302/01022
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides engineered human alpha-galactosidase polypeptides and compositions thereof. The engineered human alpha-galactosidase polypeptides have been optimized to provide improved thermostability, serum stability, improved cellular uptake, stability under both acidic (pH<4) and basic (pH>7) conditions, reduced immunogenicity, and improved globotriaosylceramide removal from cells. The invention also relates to the use of the compositions comprising the engineered human alpha-galactosidase polypeptides for therapeutic purposes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.